Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5666
Abstract: Introduction: B-cell lymphoma 2 (BCL2) inhibition is an established treatment strategy in CLL/SLL with the potential to induce deep responses. CLL/SLL treatment guidance in China is similar to that in Western countries; however, novel treatments… read more here.
Keywords: treatment; cll sll; blood; count decreased ... See more keywords
Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.3012
Abstract: 3012 Background: MHB088C is an investigational B7H3-directed ADC, created by coupling a humanized anti-B7H3 monoclonal antibody with a highly potent DNA topoisomerase I inhibitor (5~10 times more potent than DXd). Preclinical studies demonstrated robust binding… read more here.
Keywords: phase study; dna topoisomerase; topoisomerase inhibitor; count ... See more keywords
BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3024
Abstract: 3024 Background: BAT8008 is a monoclonal ADC that delivers exatecan to cells expressing TROP-2. TROP-2 is a cell surface glycoprotein that can be expressed in certain normal tissue but is frequently overexpressed in multiple carcinomas… read more here.
Keywords: pts enrolled; adc; tumor; count decreased ... See more keywords